Floatz logo

Olaparib

Paclitaxel

AstraZenecaSmall moleculePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the Paclitaxel cohort.

Asset / SponsorPhaseRating
D-thioctic acid
Ain Shams University
Phase 4BB
DL-6,8-THIOCTIC ACID
Ain Shams University
Phase 4BB
Chiauranib
Chipscreen Biosciences, Ltd.
Phase 3B
Carboplatin
AstraZeneca
Phase 1CC
CIS-DIAMMINEDICHLOROPLATINUM II
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 1CC

Same molecule, other indications

Olaparib is also rated in:

breast carcinomaDormant
BBB
Indicative ·
73 / 100
View asset →
fallopian tube serous adenocarcinomaDormant
BBB
Indicative ·
72 / 100
View asset →
ovarian carcinomaDormant
BB
Indicative ·
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →